Eric Dyess, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1699783928
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $812,152 of the $884,752 with a category attached, or 91.8%. 56 manufacturers reported payments, led by Novo Nordisk at 41.5% of the total. Reporting peaked in 2019 at $288,946 and has fallen 61.7% since, to $110,808 in 2025. Among endocrinology, diabetes & metabolism clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,688 payments — averaging $524.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$367K
- AstraZeneca$271K
- Bayer$81K
- Johnson & Johnson$57K
- Merck$49K
- Corcept Therapeutics$24K
- plus $35K from 50 others
What the payments were for
- Consulting fees$4990%
- Speaking & faculty fees$812,15292%
- Travel & lodging$40,3255%
- Food & beverage$31,4884%
- Education$2890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$884,752 in reported general payments places this provider in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 326 | $395,622 |
| Tresiba Flextouch U-200Insulin Degludec | 161 | $223,318 |
| MounjaroTirzepatide | 148 | $173,983 |
| JardianceEmpagliflozin | 179 | $150,412 |
| FarxigaDapagliflozin Propanediol | 214 | $149,269 |
| Tresiba Flextouch U-100Insulin Degludec | 116 | $78,289 |
| JanuviaSitagliptin Phosphate | 73 | $54,332 |
| KerendiaFinerenone | 62 | $51,323 |
| RybelsusSemaglutide | 52 | $45,724 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 60 | $35,155 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 40 | $28,116 |
| Xigduo XrDapaglifloz Propaned/Metformin | 41 | $27,568 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 19 | $25,176 |
| SynthroidLevothyroxine Sodium | 330 | $23,534 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 44 | $21,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog | $367,141 | $473,531421 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $447 | $189,134248 claims |
| Lilly USA, LLCMounjaro | $1,398 | $173,983148 claims |
| AstraZenecaFarxiga | $271,267 | $149,269214 claims |
| MerckJanuvia, Janumet Xr, Janumet | $49,051 | $99,845144 claims |
| BayerKerendia | $81,445 | $51,32362 claims |
| AbbVieSynthroid | $12,039 | $23,534330 claims |
| Johnson & JohnsonInvokana | $56,529 | $14,35915 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $3,529506 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Amanda SchieferJackson$204K
- John SistrunkJackson$41K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Jana PhillipsJackson$8K
- Robert EvansJackson$8K
- Christina GloverJackson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.